Liquidia Corporation $LQDA is Seven Fleet Capital Management LP’s 8th Largest Position

Seven Fleet Capital Management LP increased its holdings in Liquidia Corporation (NASDAQ:LQDA) by 124.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 204,876 shares of the company’s stock after purchasing an additional 113,609 shares during the period. Liquidia makes up about 2.4% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 8th largest position. Seven Fleet Capital Management LP’s holdings in Liquidia were worth $7,732,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. TCG Crossover Management LLC bought a new stake in shares of Liquidia in the 3rd quarter worth about $38,887,000. MPM Bioimpact LLC lifted its holdings in shares of Liquidia by 600.4% in the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after acquiring an additional 1,200,869 shares during the last quarter. Voloridge Investment Management LLC purchased a new position in Liquidia in the third quarter worth about $12,571,000. Bank of America Corp DE grew its position in Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after acquiring an additional 360,372 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Liquidia by 428.3% during the fourth quarter. Invesco Ltd. now owns 420,621 shares of the company’s stock worth $14,507,000 after acquiring an additional 341,009 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Insider Activity at Liquidia

In other Liquidia news, CAO Dana Boyle sold 1,600 shares of Liquidia stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $87.53, for a total value of $140,048.00. Following the transaction, the chief accounting officer owned 167,919 shares in the company, valued at $14,697,950.07. The trade was a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Stephen M. Bloch sold 100,000 shares of the business’s stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $89.48, for a total transaction of $8,948,000.00. Following the completion of the transaction, the director owned 501,477 shares of the company’s stock, valued at $44,872,161.96. This represents a 16.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 2,200,754 shares of company stock valued at $144,924,608 over the last 90 days. Company insiders own 25.60% of the company’s stock.

Liquidia Stock Down 3.1%

Liquidia stock opened at $84.11 on Friday. The business has a fifty day moving average of $73.77 and a two-hundred day moving average of $51.95. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The firm has a market cap of $7.48 billion, a P/E ratio of 600.83 and a beta of 0.55. Liquidia Corporation has a twelve month low of $16.82 and a twelve month high of $91.10.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. The business’s revenue for the quarter was up 4187.1% compared to the same quarter last year. On average, analysts forecast that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Bank of America restated a “neutral” rating and set a $79.00 price target (up from $64.00) on shares of Liquidia in a report on Monday, June 29th. Oppenheimer set a $75.00 price objective on shares of Liquidia in a research report on Friday, June 5th. Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Needham & Company LLC raised their target price on shares of Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Finally, Stephens set a $130.00 price target on shares of Liquidia in a research note on Friday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Liquidia has a consensus rating of “Moderate Buy” and an average price target of $86.18.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).